Posted: Wednesday, July 27, 2022
A study published in the Journal of Experimental & Clinical Cancer Research has identified the gene TEAD4 as a prognostic biomarker and potential target for the treatment of metastatic bladder cancer. “We found that TEAD4 is a powerful predictor of poor prognosis and promotes epithelial-to-mesenchymal transition of bladder cancer cells through activating [the] PI3K/AKT pathway, resulting in the enhancement of cell migration and invasion,” stated Biao Wang, PhD, of China Medical University, Shenyang, and colleagues.
The researchers used the linear models for microarray data (limma) R package to identify the differentially expressed genes between the normal samples and the tumor samples from The Cancer Genome Atlas and the Genotype-Tissue Expression databases. Of the 1,592 differentially expressed genes that were recognized, 4 were identified via Kaplan-Meier and UniCox analysis as independent prognostic factors for bladder cancer—FASN, IGFL2, PLOD1, and TEAD4.
TEAD4 had the most positive correlation with epithelial-to-mesenchymal transition, a process associated with bladder cancer progression. Expression of TEAD4 also appeared to correlate with primary tumor stage, tumor stage, and tumor grade. Additionally, the pathway inhibitor LY294002 blocked the TEAD4-induced enhancement of migration and invasion via the PI3K/AKT signaling pathway, suggesting TEAD4 may prove to be a viable target for treatment of metastatic bladder cancer.
Disclosure: The study authors reported no conflicts of interest.